L26/O-265 Evaluation of a semi-automated vitrification system based on a novel hydrogel chip for human and mouse oocyte cryopreservation: from survival to live birth
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.263 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von S. Wang und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does a novel semi-automated vitrification system utilizing microfluidic hydrogel chips achieve comparable survival, embryonic development, and live birth outcomes to manual methods? Summary answer The semi-automated system achieved >93% survival in human oocytes and demonstrated equivalent fertilization, blastocyst formation, and live birth rates to manual methods in mouse models. What is known already Oocyte vitrification is a cornerstone of fertility preservation but remains highly dependent on manual proficiency. Current manual protocols (e.g., Cryotop) are labor-intensive and prone to inter-operator variability. There is an unmet clinical need for standardized, automated vitrification platforms. However, proving the safety of such systems requires validating not just survival, but also the oocyte’s functional competence to support fertilization, embryonic development, and healthy live births compared to gold-standard manual methods. Study design, size, duration This validation study consisted of two parts. First, a preclinical validation using human metaphase II (MII) oocytes (n = 550 total cycles) assessed system consistency and survival. Second, a comprehensive prospective study using B6D2F1 mouse oocytes compared three groups: semi-automated system (Biorocks), manual Cryotop (Manual), and fresh control (Fresh). This arm evaluated subcellular safety, mitochondrial function, and importantly, developmental competence via intracytoplasmic sperm injection (ICSI) and embryo transfer to assess live birth outcomes. Participants/materials, setting, methods Human MII oocytes derived from in vitro maturation (IVM) were obtained from consented patients at a university-affiliated center for survival assays, following ethical approval (no. 2022-670-01). Mouse oocytes underwent vitrification/warming followed by ICSI. Fertilization (2-cell), blastocyst formation, and live birth rates (after transfer to pseudopregnant females) were recorded. Safety endpoints included spindle/chromosome integrity (immunofluorescence), mitochondrial reactive oxygen species (ROS) levels, and DNA fragmentation (TUNEL). Statistical comparisons utilized ANOVA and Chi-square tests. Main results and the role of chance With human oocyte, the semi-automated system achieved high consistency with 93.75% (60/64) survival in single-thaw and 94.44% (459/486) in cumulative cycles. In the mouse model, Biorocks showed comparable spindle morphology (82.90%) and chromosome alignment (95.10%) to Manual (84.80%, 91.30%; P > 0.05). ROS levels were significantly lower in Biorocks (100.70 ± 1.27 AU) versus Manual (107.76 ± 1.65 AU, P < 0.05), indicating reduced oxidative stress. Furthermore, TUNEL assays demonstrated no detectable positive signals in any group. For developmental & live birth outcomes, in the mouse model, both Biorocks (n = 93) and Manual (n = 60) achieved 100% post-thaw survival. Degeneration rates after ICSI were comparable (Biorocks 10.00% (6/60) vs. Manual 8.33% (5/60) vs. Fresh 11.25% (9/80); P > 0.05) Post-ICSI, Biorocks fertilization (2-cell) rates were 90.74% (49/54), comparable to Manual (96.36%, 53/55) and Fresh (91.55%, 65/71; P > 0.05). Blastocyst formation per 2-cell embryo in Biorocks (85.71%, 42/49) was comparable to Manual (77.36%, 41/53; P > 0.05), while Fresh controls reached 96.92% (63/65). Crucially, live birth rates per transferred embryo showed no significant difference: Biorocks (42.50%, 17/40) vs. Manual (45.00%, 18/40) vs. Fresh (51.67%, 31/60; P > 0.05), confirming preserved developmental competence. Limitations, reasons for caution Human oocytes used were derived from IVM, which may differ physiologically from in vivo matured oocytes. Sample sizes for live birth data in the mouse model are relatively small, though the outcomes are promising. Full clinical trials are required to confirm equivalence in human pregnancy outcomes. Wider implications of the findings This hydrogel-based system successfully automates critical cryoprotectant agent (CPA) loading steps, reducing operator variability. By demonstrating equivalent competence to support fertilization, blastocyst development, and live births alongside superior mitochondrial protection, this technology offers a safe, scalable, and standardized solution for clinical IVF laboratories. Trial registration number No
Zitieren
APA
Wang, S., Chen, L., & Sun, H. (2026). L26/O-265 Evaluation of a semi-automated vitrification system based on a novel hydrogel chip for human and mouse oocyte cryopreservation: from survival to live birth. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.263
Vancouver
Wang S, Chen L, Sun H. L26/O-265 Evaluation of a semi-automated vitrification system based on a novel hydrogel chip for human and mouse oocyte cryopreservation: from survival to live birth. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.263
BibTeX
@article{Wang2026,
author = {Wang, S. and Chen, L. and Sun, H.},
title = {L26/O-265 Evaluation of a semi-automated vitrification system based on a novel hydrogel chip for human and mouse oocyte cryopreservation: from survival to live birth},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.263}
}
EUVIMED